Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:58:36 EDT Mon 14 Oct 2024
Enter Symbol
or Name
USA
CA



Q:NBIX - NEUROCRINE BIOSCIENCES INC - http://WWW.NEUROCRINE.COM
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NBIX - Q2.0116.40·116.461.0116.44+0.950.8332.838,1977,301115.13  116.47  115.03157.9799  103.6315:37:58Oct 0915 min RT 2¢

Recent Trades - Last 10 of 7301
Time ETExPriceChangeVolume
15:38:04Q116.41840.92845
15:37:58Q116.41770.9277100
15:37:55Q116.41770.927741
15:37:53Q116.430.9424
15:37:52Q116.41750.92752
15:37:49Q116.4280.93850
15:37:49Q116.39610.9061100
15:37:46Q116.41750.927539
15:37:46Q116.42150.931521
15:37:42Q116.37170.881722

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-09 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
2024-09-30 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
2024-09-19 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
2024-09-12 16:05U:NBIXNews ReleaseNeurocrine Biosciences Provides Update on ERUDITE(TM) Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
2024-09-10 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
2024-08-28 16:05U:NBIXNews ReleaseNeurocrine Biosciences to Participate at Investor Conferences in September
2024-08-28 07:00U:NBIXNews ReleaseNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
2024-08-07 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
2024-08-01 07:00U:NBIXNews ReleaseNeurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
2024-07-18 08:30U:NBIXNews ReleaseNeurocrine Biosciences Launches INGREZZA(TM) SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
2024-07-11 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
2024-07-01 07:30U:NBIXNews ReleaseNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
2024-06-03 08:01U:NBIXNews ReleaseNeurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
2024-06-03 07:35U:NBIXNews ReleaseNeurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
2024-06-03 07:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
2024-05-29 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Participate at Investor Conferences in June
2024-05-28 16:14U:NBIXNews ReleaseNeurocrine Biosciences Announces CEO Succession Plan
2024-05-28 08:30U:NBIXNews ReleaseNeurocrine Biosciences to Present New Phase 3 CAHtalyst(TM) Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
2024-05-21 16:05U:NBIXNews ReleaseNeurocrine Biosciences Announces Publication of Phase 3 KINECT(TM)-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA(TM) (valbenazine) Capsules
2024-05-14 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presented Baseline Data from the CAHtalyst(TM) Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024